摘要
目的 研究法洛四联症(TOF)矫治术后早期B型利钠肽(BNP)的水平,观察内皮素受体拮抗剂对BNP的影响.方法 2010年1月至2012年1月,32例患儿行TOF矫治术,男20例,女12例;年龄4~18岁,平均(7.64±3.75)岁,手术前均已行心脏增强CT检查并评价肺血管和左心室发育情况.术后患儿根据病案号按单双号分为两组:A组14例,术后≤3天按照推荐剂量服用波生坦;B组18例,术后不服用波生坦及任何内皮素受体拮抗剂类药物.术后第10天分别复查心脏超声及实验室检查并做临床评估.结果 术后第10天两组患儿均无死亡病例.两组患儿基线资料及术中资料差异无统计学意义.A组BNP水平显著低于B组;在正性肌力药物用量方面,A组评分明显低于B组.在三尖瓣反流、肺动脉瓣反流状况以及左/右心室比值、肝功能方面比较两组数据差异无统计学意义.心功能A组略优于B组,但差异无统计学意义.结论 TOF矫治术后早期使用内皮素受体拮抗剂可以显著改善出院时患儿的BNP水平,减少术后正性肌力药物的使用.
Objective To determine the brain natriuretic peptide(BNP) levels and the effects of endothelin receptor antagonist(ERA) on BNP levels in patients with tetralogy of Fallot(TOF) recently surgical repaired.Methods During January 2010 to January 2012,32 cases of TOF after surgical repaired in hospital were selected.There are 20 males and 12 females,Aged 4 years to 18 years [mean age (7.64±3.75) years] in age.All patients underwent enhanced CT to evaluate the pulmonary vessels and left ventricular before surgery arrangements.As the surgeries done,the patients were grouped randomly as either A or B.All 14 patients in group A started to follow the recommended dosage of bosentan within 3 days after surgery.Meanwhile,all 18 in group B had not taken bosentan or any other ERAs since the surgeries.Both group was evaluated and examined with echocardiography and blood test at the 10th day after surgery.Results None of the patients died within 10 days after surgery.BNP levels of group A was significantly lower than of group B.Inotropic score of group A was markedly lower,too.However,although group A showed mildly advantages in tricuspid regurgitation,pulmonary regurgitation,ratio of RV/LV end-systolic dimension and liver functions,there was no statistically significant difference.Conclusion For patients with tetralogy of Fallot,early use of ERAs after surgical repaired could reduce the use of inotropic agents and significantly decrease the BNP levels when discharged.
出处
《中华胸心血管外科杂志》
CSCD
北大核心
2014年第10期590-593,共4页
Chinese Journal of Thoracic and Cardiovascular Surgery
基金
湖北省卫生厅科研项目(JX6890)
武汉市卫生局科研项目(WXl3C47)
关键词
法乐氏四联症
内皮素受体拮抗剂
内皮素-1
利钠肽
脑
Tetralogy of Fallot Endothehn receptor antagonist Endothelin -1 Natriuretic peptide, brain